Partner Description
CRELUX GmbH is a fully independent integrated drug discovery solutions company located in Munich, Germany. The company is led by its founders and owners and provides solutions in protein production, in-vitro-activity and binding assays and X-ray crystallography.
i2C is a joint venture between CRELUX and 4SC Discovery GmbH to provide an integrated drug discovery platform (idea to candidate) which offers a seamless process from early concept through to a preclinical development candidate ready to advance into formal animal model testing and thereafter into clinical trails.
i2C, CRELUX and 4SC Discovery are operating from shared facility where 4SC Discovery adds strong in silico screening and medicinal chemistry capacities, as well as a team of experienced pharmacologists that has successfully brought a number of small molecule drugs from discovery to clinical trials.
Role
CRELUX leads Work Package 3 (anti-ageing and angiogensis bioassays) and will also be involved in WP6 and WP8.